Researchers show that graphene quantum dots can block SARS-CoV-2 Variant from entering cells

A recent study has reported the use of human host defense peptide-conjugated graphene quantum dots for the prevention of virus entry into host cells.

Research on the SARS-CoV-2 virus mainly focuses on the spike protein (S1) which contains the receptor-binding domain (RBD) and the binding of this to the angiotensin converting enzyme 2 (ACE2) receptor within epithelial cells enables the virus to enter host cells in humans. This research resulted in the spike protein becoming a target for vaccines that aimed to produce neutralizing antibodies against the S-RBD. But while this concept seemed useful, recent reports have suggested the mutations on the SARS-CoV-2 virus and specifically in the S-RBD, can cause a decline in the level of neutralizing antibodies against the delta (B.1.617.2) variant that may have been produced during a previous infection or from immunization via a vaccine.

In light of these reports, researchers have strategized an innovative solution for blocking the interaction between the spike protein and the ACE2 receptor to prevent infections from mutating variants.

The new research is premised on the fact that approximately 42% of the infected population are asymptomatic, which can suggest that the COVID-19 infection can be effectively controlled by the innate immune system.

This system is the first defense against pathogens coming into the body such as viruses and bacteria; this activates an immune response to destroy the pathogen while the adaptive immune response is modulated which causes immune cells to multiply and fight against the infection and ultimately, result in recovery.

Critical components of the innate immune system consist of peptides such as α-Defensin human neutrophil peptides (HNP1, HNP2, HNP3, and HNP4) and human β-defensins (HBD1, HBD2, and HBD3) as well as LL-37 (leucine-leucine-37) cathelicidin family peptides.

Defensins and cathelicidin peptides hold an important function in viral inhibition through binding and destabilization.

Researchers of this study aimed to block the delta variant and the subsequent infection from the SARS-CoV-2 virus through the use of an innovative design of HNP1 and LL-37 peptide-conjugated graphene quantum dots (GQDs). This novel development has the ability to bind to the delta variant S-RBD and block the binding to the ACE2 receptor in host cells, preventing the virus from entering the host cell, and therefore prevent COVID-19 infection.

The development of graphene quantum dots is a novel innovation that comprises a graphene lattice as well as graphene sheets that exhibit size-dependent luminescence properties due to quantum confinement and edge effects. These GQDs consist of surface groups including, carboxy, epoxy, and hydroxyl which illustrate high water solubility, high surface area as well as high photostability.

The unique optical properties of GQDs allow this candidate to be highly useful in applications such as bioimaging and biosensing; however, it can also be used innovatively to monitor the status of the delta variant of the SARS-CoV-2 virus.

The bioconjugated GQD fluorescence in this research study has been used to monitor the spike RBD and ACE2 receptor interaction to determine the effective binding affinity. Additionally, the functional groups on the GQDs have also been used to inactivate the virus through decomposing the lipid membrane of the virus and removing the spike proteins attached to the lipid membrane.

This research illustrates the double usage of this quantum dot strategy which would first be used to monitor the delta variant and compete for the S-RBD-ACE2 interaction to prevent this critical attachment, as well as attempt to remove the spike proteins from the lipid membrane to also prevent this interaction.

The binding affinity for the delta variant in comparison to the alpha, beta, and gamma variant spike-RBD was shown to be higher using this innovative strategy. This can be useful as this advancement would enable the complete inhibition of the delta variant from the host cell.

This research may enhance the defense against the coronavirus and its emerging variants, with the possibility of modification for other emerging variants of concern. Additionally, this could also be translated for use against other viruses in order to increase protection against pathogens.

Posted: Mar 06,2022 by Roni Peleg